Methylflurbiprofen

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methylflurbiprofen
• 英文别名: 2-(2-fluoro-1,1'-biphenyl-4-yl)-2-methylpropanoic acid；2-(2-Fluoro[1,1'-biphenyl]-4-yl)-2-methylpropanoic acid；2-(2-fluoro-1,1'-biphenyl-4-yl)-2-methylpropionic acid；2-(2-fluoro-1,1-biphenyl-4-yl)-2-methylpropionic acid；2-(2-Fluoro-biphenyl-4-yl)-2-methyl-propionic acid；2-(3-fluoro-4-phenylphenyl)-2-methylpropanoic acid
• 化学式: C₁₆H₁₅FO₂
• 分子量: 258.292
• InChiKey: UTJOTVGFUYHIRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Methylflurbiprofen 在 四丁基醋酸铵 作用下， 以 乙腈 为溶剂， 以69 %的产率得到2-fluoro-4-(prop-1-en-2-yl)-1,1'-biphenyl
  参考文献：
  名称：

  电化学脱羧消除羧酸生成烯烃

  摘要：

  已经开发出一种在室温下将羧酸脱羧消除为烯烃的电化学策略。这种温和且无氧化剂的方法为传统热脱羧反应提供了一种绿色替代方案。结构多样的脂肪族羧酸，包括生物活性药物，以良好到优异的产率顺利转化为相应的烯烃。

  DOI：

  10.1021/acs.orglett.3c02997
• 作为产物：
  描述：

  氟比洛芬 在 硫酸 、 potassium trimethylsilonate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 Methylflurbiprofen
  参考文献：
  名称：

  Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes

  摘要：

  Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid and the endocannabinoids 2-arachidonoylglycerol (2-AG) and arachidonoylethanolamide (AEA). We recently reported that (R)-profens selectively inhibit endocannabinoid oxygenation but not arachidonic acid oxygenation. In this work, we synthesized achiral derivatives of five profen scaffolds and evaluated them for substrate-selective inhibition using in vitro and cellular assays. The size of the substituents dictated the inhibitory strength of the analogs, with smaller substituents enabling greater potency but less selectivity. Inhibitors based on the flurbiprofen scaffold possessed the greatest potency and selectivity, with desmethylflurbiprofen (3a) exhibiting an IC50 of 0.11 mu M for inhibition of 2-AG oxygenation. The crystal structure of desmethylflurbiprofen complexed to mCOX-2 demonstrated a similar binding mode to other profens. Desmethylflurbiprofen exhibited a half-life in mice comparable to that of ibuprofen. The data presented suggest that achiral profens can act as lead molecules toward in vivo probes of substrate-selective COX-2 inhibition.

  DOI：

  10.1021/ml3001616

文献信息

• ISOTOPE LABELED 2-ARYLPROPIONIC ACID COMPOUNDS AND PROCESS FOR PRODUCTION OF SAME, AND MOLECULAR PROBE FOR POSITRON EMISSION TOMOGRAPHY AND METHOD FOR IMAGING OF CYCLOOXYGENASE AND THE LIKE USING SAME
  申请人：Takashima Misato

  公开号：US20120128588A1

  公开（公告）日：2012-05-24

  Disclosed are: labeled NSAIDs compounds which can be produced within a short time, can be used suitably for a PET method, and enable the imaging of cyclooxygenase-2; and a process for producing the labeled NSAIDs compounds. Specifically disclosed are isotope-labeled 2-arylpropionic acid compounds, each of which is a compound represented by general formula (1) (wherein Ar represents an aryl group which may have a substituent; R 1 represents anyone selected from 11 CH 3 , CH 2 18 F and CF 2 18 F; and R 2 represents a hydrogen atom, or an alkyl group which may have a branch, wherein a compound wherein Ar is a benzene ring, R 1 is 11 CH 3 , and R 2 is a hydrogen atom is excluded), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

  披露了：标记的NSAIDs化合物可以在短时间内生产，适用于PET方法，并能够成像环氧合酶-2；以及制备标记的NSAIDs化合物的方法。具体披露的是同位素标记的2-芳基丙酸化合物，每个化合物都是由通式（1）表示的化合物（其中Ar代表可能具有取代基的芳基；R1代表从11CH3、CH218F和CF218F中选择的任一种；R2代表氢原子，或可能具有支链的烷基，其中Ar为苯环，R1为11CH3，R2为氢原子的化合物被排除），或其药用可接受的盐、水合物、溶剂合物或前药。
• Method and composition for treating neurodegenerative disorders
  申请人：Hobden Adrian

  公开号：US20050288375A1

  公开（公告）日：2005-12-29

  The invention provides compositions and methods for treating neurodegenerative disorders. A method of the invention involves administering to an individual in need of treatment a composition having an R-NSAID and an NMDA antagonist. Another method of the invention involves administering to an individual in need of treatment a composition having at least two compounds that are capable of interacting with CYP2C9, wherein at least one of said compounds is an Aβ 42 lowering agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment.

  本发明提供了用于治疗神经退行性疾病的组合物和方法。该发明的一种方法涉及向需要治疗的个体施用具有R-NSAID和NMDA拮抗剂的组合物。该发明的另一种方法涉及向需要治疗的个体施用至少两种能够与CYP2C9相互作用的化合物的组合物，其中至少一种化合物是Aβ42降低剂。该发明的方法和组合物对于治疗和预防像阿尔茨海默病、痴呆症、轻度认知障碍等神经退行性疾病非常有用。
• Geminallyl di-substituted nsaid derivatives as abeta 42 lowering agents
  申请人：Munoz Benito

  公开号：US20060063937A1

  公开（公告）日：2006-03-23

  The present invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, wherein A is the base molecule of a propionic acid or acetic acid NSAID, or a derivative thereof, X is —CO 2 H, 1H-tetrazol-5-yl or 2H-tetrazol-5-yl and R 1 and R 2 are each independently selected from the group consisting of: C 1-6 alkyl and C 3-6 cycloalkyl, as well as pharmaceutical composition comprising said compounds and methods of using said compounds. The compounds of the present invention lower the level of Aβ 42 and are therefore useful for preventing, delaying or reversing the progression of Alzheimer s Disease.

  本发明涵盖公式I（I）的化合物或其药学上可接受的盐，其中A是丙酸或乙酸非甾体抗炎药的基本分子或其衍生物，X为-CO2H，1H-四唑-5-基或2H-四唑-5-基，R1和R2各自独立地选自以下组：C1-6烷基和C3-6环烷基，以及包括所述化合物的制药组合物和使用所述化合物的方法。本发明的化合物降低Aβ42的水平，因此有助于预防、延缓或逆转阿尔茨海默病的进展。
• Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders
  申请人：Hobden Adrian

  公开号：US20070232656A1

  公开（公告）日：2007-10-04

  The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase inhibitor and another therapeutic agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, and mild cognitive impairment.

  本发明提供了治疗神经退行性疾病的组合物和方法。本发明的方法涉及向需要治疗的个体施用一种含有乙酰胆碱酯酶抑制剂和另一种治疗剂的组合物。本发明的方法和组合物对于治疗和预防阿尔茨海默病、痴呆和轻度认知障碍等神经退行性疾病是有用的。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。